NCT01837667View on ClinicalTrials.gov

Phase I Study of LB-100 With Docetaxel in Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
TumorsNeoplasmsCancer
Interventions
DRUG

LB-100 for Injection

Part 1 and Part 2: LB-100 for Injection infusion on Days 1,2,3 of each 21 day cycle.

DRUG

Docetaxel

Part 2: Docetaxel infusion on Day 2 of each 21 day cycle.

Trial Locations (5)

55905

Mayo Clinic, Rochester

75246

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas

75702

Texas Oncology - Tyler, Tyler

89169

Comprehensive Cancer Centers of Nevada, Las Vegas

91010

City of Hope National Medical Center, Duarte

Sponsors
All Listed Sponsors
lead

Lixte Biotechnology Holdings, Inc.

INDUSTRY